BioVaxys Technology Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jul '25 Jul 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	2019
Selling, General & Admin	4.2	2.82	2.12	2.34	4.12	0.42	Upgrade
Research & Development	0.03	0	0.13	0.96	0.73	0.24	Upgrade
Operating Expenses	4.64	3.12	2.4	3.8	5.98	1.01	Upgrade
Operating Income	-4.64	-3.12	-2.4	-3.8	-5.98	-1.01	Upgrade
Interest & Investment Income	-	-	-	-	0	0	Upgrade
Currency Exchange Gain (Loss)	-0.05	-0	-0.03	-0.02	-0.02	-0	Upgrade
Other Non Operating Income (Expenses)	-0.19	-0.17	-4.03	-0.26	-0.46	-0.09	Upgrade
EBT Excluding Unusual Items	-4.88	-3.3	-6.46	-4.08	-6.46	-1.1	Upgrade
Asset Writedown	-1.29	-1.29	-1.45	-7.4	-	-	Upgrade
Other Unusual Items	0.2	0.63	0.21	-0.25	-	-	Upgrade
Pretax Income	-5.97	-3.95	-7.69	-11.73	-6.46	-1.1	Upgrade
Earnings From Continuing Operations	-5.97	-3.95	-7.69	-11.73	-6.46	-1.1	Upgrade
Earnings From Discontinued Operations	-	-	-	-	-	-0.07	Upgrade
Net Income	-5.97	-3.95	-7.69	-11.73	-6.46	-1.17	Upgrade
Net Income to Common	-5.97	-3.95	-7.69	-11.73	-6.46	-1.17	Upgrade
Shares Outstanding (Basic)	28	20	13	10	8	3	Upgrade
Shares Outstanding (Diluted)	28	20	13	10	8	3	Upgrade
Shares Change (YoY)	61.26%	45.90%	36.63%	18.39%	193.97%	171.65%	Upgrade
EPS (Basic)	-0.22	-0.20	-0.57	-1.19	-0.78	-0.42	Upgrade
EPS (Diluted)	-0.22	-0.20	-0.57	-1.19	-0.78	-0.42	Upgrade
EBIT	-4.64	-3.12	-2.4	-3.8	-5.98	-1.01	Upgrade
Advertising Expenses	-	0.42	-	0.17	1.72	0.08	Upgrade

Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.